10-K: Aquestive Therapeutics Expands Libervant License, Files Pediatric NDA

Aquestive Therapeutics amended its license agreement with Pharmanovia to expand the territory for Libervant and filed an NDA for pediatric use of the drug.

Summary

• Aquestive Therapeutics amended its existing license and supply agreement with Pharmanovia, expanding the territory for Libervant to include all countries worldwide except the USA, Canada, and China.
• The amendment, effective March 27, 2023, included a $2 million non-refundable payment to Aquestive.
• The agreement also restated product schedule 1 of the original agreement, and modified sections related to technical consultation, profit sharing, and delivery quantities.
• Aquestive filed an NDA for Libervant for the acute treatment of seizures in children aged two to five years, with a PDUFA goal date of April 28, 2024.
• The original agreement was signed on September 26, 2022.
• The agreement includes milestone payments for the original and extended territories, as well as sales milestones in the extended territories.
• The product transfer price for the original territory will be COGS plus 10% if Pharmanovias profit/net sales falls below 30% on a rolling 12-month basis.
• Aquestive will receive a 40% profit share in the original territory if Pharmanovias profit/net sales falls below 30% on a rolling 12-month basis.
• Pharmanovia is required to file for regulatory approval in the original territory within three years of the amendment's effective date or the agreement may be terminated.
• Aquestive is responsible for the preparation, filing, prosecution and maintenance of Aquestive Patents in the original territory, with costs borne by Aquestive.

Sentiment

Score: 8

Explanation: The document is positive due to the expansion of the license agreement and the filing of the pediatric NDA, indicating growth potential and future revenue streams. The financial terms of the agreement are also favorable for Aquestive.

Positives

• The expansion of the Libervant license territory significantly increases the potential market for the drug.
• The $2 million non-refundable payment provides immediate capital to Aquestive.
• The filing of the pediatric NDA for Libervant represents a significant step towards expanding the drugs availability to a younger patient population.
• The profit share agreement provides a potential upside for Aquestive if Pharmanovias sales are lower than expected.
• The agreement includes milestone payments for the original and extended territories, as well as sales milestones in the extended territories.

Negatives

• The agreement includes a clause that allows Pharmanovia to request a reduction in the product transfer price if their profit/net sales falls below 30%.
• The agreement can be terminated if Pharmanovia does not file for regulatory approval in the original territory within three years of the amendment's effective date.

Risks

• There is a risk that Pharmanovias profit/net sales could fall below 30%, triggering a reduction in the product transfer price.
• There is a risk that Pharmanovia may not file for regulatory approval in the original territory within three years, leading to termination of the agreement.
• The success of Libervant in the expanded territories is dependent on Pharmanovias ability to obtain regulatory approvals and effectively commercialize the drug.
• The agreement includes a clause that allows Pharmanovia to request a discussion regarding the product transfer price and royalty payments for the product in the extended territories if their profit/net sales falls below 30%.

Future Outlook

The document outlines the expansion of the Libervant license and the filing of a pediatric NDA, indicating a focus on growth and market expansion for the drug. The agreement also includes future milestone payments and profit sharing, suggesting potential for increased revenue for Aquestive.

Industry Context

This announcement reflects a trend in the pharmaceutical industry towards expanding the reach of existing drugs into new markets and patient populations. The focus on pediatric use and global expansion aligns with strategies to maximize the commercial potential of pharmaceutical products.

Comparison to Industry Standards

• The agreement structure, including upfront payments, milestone payments, and royalties, is typical for pharmaceutical licensing agreements.
• The profit share arrangement is a common mechanism to align the interests of both parties in the event of lower than expected sales.
• The three-year timeline for regulatory approval in the original territory is a standard timeframe for pharmaceutical product launches.
• The expansion of the license territory to include most of the world outside of the US, Canada and China is a significant move, similar to other pharmaceutical companies seeking global reach for their products.

Stakeholder Impact

• Shareholders: The agreement and NDA filing are positive developments that could increase the value of the company.
• Employees: The expansion of the license agreement and the filing of the pediatric NDA could lead to increased job security and potential for growth.
• Customers: The agreement could lead to increased availability of Libervant in new markets.
• Suppliers: The agreement could lead to increased demand for Aquestives manufacturing capabilities.
• Creditors: The agreement and NDA filing could improve the companys financial stability and ability to repay debts.

Next Steps

• Pharmanovia will seek regulatory approval for Libervant in the expanded territories.
• Aquestive will continue to manufacture and supply Libervant to Pharmanovia.
• The FDA will review the pediatric NDA for Libervant, with a PDUFA goal date of April 28, 2024.

Key Dates

Keywords

Libervant, Pharmanovia, License Agreement, Diazepam, Seizures, Buccal Film, Regulatory Approval, Territory Expansion, Milestone Payments, Profit Share